Ramelteon for Insomnia Comorbid With Asthma
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This trial will test the efficacy and safety of ramelteon, a selective melatonin agonist, on patients with insomnia comorbid with asthma.
| Condition | Intervention | Phase |
|---|---|---|
|
Insomnia Asthma |
Drug: Ramelteon |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Ramelteon for Insomnia Comorbid With Asthma |
- Pittsburgh Sleep Quality Index [ Time Frame: baseline and post-treatment (at end of 5 weeks) ] [ Designated as safety issue: No ]
The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms
- Insomnia Severity Index [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms
- Daytime Sleepiness (Epworth Sleepiness Scale) [ Time Frame: baseline and post-treatment (at end of 5 weeks) ] [ Designated as safety issue: No ]Score of 0-24, with 24 being the most sleepy
- Daytime Performance (Digit Symbol Substitution Test) [ Time Frame: baseline and post-treatment (at end of 5 weeks) ] [ Designated as safety issue: No ]
DSST tests the number of correct digit-symbol pairs that an individual can identify within an allotted period (60-90 sec). It test memory and concentration, among other parameters.
DSST score can range from 0-125, with 125 being the most number correct during the allotted time period.
- Daytime Lung Function (Peak Flow Monitoring) in Liter/Min [ Time Frame: baseline and during treatment period (during 5th week) ] [ Designated as safety issue: Yes ]
| Enrollment: | 2 |
| Study Start Date: | March 2008 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1: Ramelteon |
Drug: Ramelteon
melatonin agonist
Other Name: Rozerem
|
| Placebo Comparator: 2: Placebo |
Drug: Ramelteon
melatonin agonist
Other Name: Rozerem
|
Detailed Description:
Subjects with insomnia comorbid with asthma will be randomized to placebo or ramelteon at night for 6 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ages 18 - 60 with both insomnia and asthma.
Insomnia:
- a complaint of difficulty initiating sleep, difficulty maintaining sleep, or waking up too early or sleep that is chronically nonrestorative or poor in quality,
- the sleep difficulty occurs despite adequate opportunity and circumstances for sleep, and
- at least one form of daytime impairment related to the nighttime sleep difficulty must be present. The sleep complaint should be present on most days for at least 3 months.
- Additional inclusion criteria include: a subjective TST <6.5 h and a subjective SL > 45 min per night; a mean LPS >20 min over 2 consecutive nights by polysomnography (neither night could have been <15 min); a habitual bedtime between 10 PM and 1 AM; and ISI score > 10 (based on 0-4 scale). LPS is defined as amount of time to the first 10 minutes of continuous sleep.
Asthma will be diagnosed based on suggestive clinical history and either
- airway hyperresponsiveness indicated by a 20% or greater decrease in FEV1 in response to inhalation of methacholine at 8 mg/mL or less
- bronchodilator-responsive expiratory airflow limitation (if FEV1 < 70% of predicted value or < 1.5 L, improving ≥200 mL and 12% in response to 180 µg of albuterol aerosol). In addition to the above criteria, patients should have well-controlled asthma as evidenced by ACQ score < 1.5.
Exclusion Criteria:
- Primary sleep pathology, other than insomnia as assessed by sleep history and confirmed by polysomnography to exclude significant sleep apnea (RDI > 15), periodic leg movements (movement arousal index > 15), REM behavior disorder; or circadian sleep-wake disorders
- History of cognitive or other neurological disorders;
- History of DSM-IV criteria for any major psychiatric disorder, including mania or alcohol or substance abuse;
- Depressive symptoms as assessed by the CES-D. Subjects with a score of 22 or greater indicates that the person may be suffering from a major depression and therefore, will be referred to their physician;
- Unstable or serious medical conditions;
- Current, or use within the past month, of psychoactive, hypnotic, stimulant or analgesic medications (except occasionally);
- Shift work or other types of self imposed irregular sleep schedules;
- Obesity (BMI > 35 Kg/m2); or
- Pregnancy or desire to become pregnant during the study.
Contacts and Locations| United States, Illinois | |
| Northwestern University | |
| Chicago, Illinois, United States, 60611 | |
| Principal Investigator: | Brandon S Lu, MD, MS | Northwestern University |
More Information
No publications provided
| Responsible Party: | Brandon Lu, Physician, Northwestern University |
| ClinicalTrials.gov Identifier: | NCT00869167 History of Changes |
| Other Study ID Numbers: | 07-052R |
| Study First Received: | March 19, 2009 |
| Results First Received: | June 28, 2011 |
| Last Updated: | April 26, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Asthma Sleep Initiation and Maintenance Disorders Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate |
Hypersensitivity Immune System Diseases Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases Mental Disorders |
ClinicalTrials.gov processed this record on May 16, 2013